Current and emerging treatment options for metastatic melanoma: a focused review

Area of Science:

• Oncology
• Immunology
• Radiation Oncology

Background:

• Melanoma causes significant mortality, with metastatic disease historically treated with chemotherapy.
• Current treatments include BRAF inhibitors, CTLA-4 blockade, and IL2 for immune stimulation.
• Advances in understanding melanoma pathogenesis have led to novel therapeutic strategies.

Purpose of the Study:

• To review historical, current, and emerging treatment modalities for metastatic melanoma.
• To evaluate the evidence and provide recommendations for various melanoma treatments.
• To highlight the potential of underutilized therapies like radiation and novel immunotherapies.

Main Methods:

• Literature review of past, present, and future melanoma treatment options.
• Analysis of therapeutic mechanisms including signal transduction inhibition, immune response modulation, and T-cell stimulation.
• Assessment of radiation therapy's abscopal effect and immune-disrupting agents like pembrolizumab.

Main Results:

• Chemotherapy was the primary treatment for metastatic melanoma until the early 2000s.
• Approved therapies target BRAF pathways, enhance anti-tumor immunity (CTLA-4 blockade), and stimulate T cells (IL2).
• Emerging strategies include radiation therapy (abscopal effect), pembrolizumab, imiquimod, adoptive T-cell therapy, and vaccines.

Conclusions:

• Treatment for metastatic melanoma has significantly advanced beyond traditional chemotherapy.
• Targeted therapies, immunotherapies, and radiation offer new avenues for managing advanced melanoma.
• Future research and clinical trials are crucial for optimizing novel treatments and improving patient outcomes.